White Papers
Our work in White Papers
-
Policy Brief: A Novel Strategy for Increasing Access to Hep C Treatment for Medicaid Beneficiaries
A state-level financing strategy could help Medicaid programs provide access to hepatitis C patients while still encouraging future pharmaceutical innovation.
-
A Proposal to Enhance Competition and Reform Bidding in the Medicare Advantage Program
Schaeffer Initiative researchers propose two key changes to the MA bidding process to lower prices and enhance choice for consumers.
-
Overpaying for Prescription Drugs: The Copay Clawback Phenomenon
In 2013, almost one quarter of filled pharmacy prescriptions (23%) involved a patient copayment that exceeded the average reimbursement paid by the insurer by more than $2.00.
Categorized in -
Prescription Drug Copayment Coupon Landscape
The researchers examined copay coupon availability for the top 200 drugs (by spending) in 2014. Of these, 132 were brand drugs, and 90 of those had coupons available.
Categorized in -
The Global Burden of Medical Innovation
Calculations using publicly available aggregate data suggest that the United States market accounts for 64 to 78 percent of worldwide pharmaceutical profits.
Categorized in -
Reining in Pharmaceutical Costs
The administration and lawmakers should prioritize four actions that could engender more cooperation and improve health over the long term.